Table 1 Baseline characteristics of subjects with type 2 diabetes mellitus and control subjects (n = 106)
Control subjects (n = 32) | T2DM subjects (n = 74) | p value | |
|---|---|---|---|
Gender, male/female | 19/13 | 37/37 | 0.4041 |
Age, years | 62 ± 1 (39-83) | 66 ± 1 (36-84) | 0.5349 |
Job type (non/employee/individual proprietor/homemaker/others) | 5/14/1/11/1 | 17/25/1/27/4 | |
Body mass index, kg/m2 | 22.7 ± 0.7 (13.9-30.8) | 24.7 ± 0.5 (17.8-34.5) | 0.0153 |
Blood glucose, mg/dL | 94 ± 3 (53-113) | 128 ± 74 (52-252) | <0.001 |
Glycoalbumin, % | 14.9 ± 1.0 (12.9-16.0) | 19.8 ± 0.6 (12.5-33.3) | 0.0243 |
HbA1c (NGSP), % | 5.9 ± 0.1 (5.4-6.3) | 7.0 ± 0.1 (5.6-14.4) | 0.0001 |
Systolic blood pressure, mmHg | 138 ± 23 (98-174) | 137 ± 2 (101-182) | 0.9149 |
Diastolic blood pressure, mmHg | 81 ± 2 (65-97) | 80 ± 1 (49-105) | 0.7800 |
Triglyceride, mg/dL | 175 ± 41 (44-1231) | 138 ± 10 (34-471) | 0.8158 |
High-density lipoprotein cholesterol, mg/dL | 62 ± 23 (31-121) | 53 ± 2 (17-103) | 0.0079 |
Low-density lipoprotein cholesterol, mg/dL | 117 ± 5 (80-196) | 112 ± 4 (64-208) | 0.3333 |
Uric acid, mg/dL | 5.5 ± 0.2 (2.8-7.8) | 5.5 ± 0.2 (2.7-9.4) | 0.9827 |
Creatinine, mg/dL | 0.70 ± 0.02 (0.46-1.15) | 0.86 ± 0.05 (0.44-2.83) | 0.0798 |
Diabetic neuropathy | - | n = 15 | |
Diabetic retinopathy (NDR/SDR/PDR) | - | n = 56/6/12 | |
Diabetic nephropathy (stage I/II/III/IV) | - | n = 57/9/3/5 | |
Drugs for diabetes (medication/insulin) | - | n = 57/17 | |
Hypertension (under medications) | n = 18 (n = 11) | n = 60 (n = 46) | 0.0151 |
Dyslipidemia (under medications) | n = 21 (n = 13) | n = 48 (n = 34) | 0.8253 |
Insomnia, under medications | n = 6 | n = 11 | 0.7736 |